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Abstract
Background: Osteoporosis is the most prevalent skeletal disorder, characterized by a low bone mineral density (BMD) and
bone structural deterioration, leading to bone fragility fractures. Accelerated bone resorption by osteoclasts has been
established as a principal mechanism in osteoporosis. However, recent experimental evidences suggest that inappropriate
apoptosis of osteoblasts/osteocytes accounts for, at least in part, the imbalance in bone remodeling as occurs in
osteoporosis. The aim of this study is to examine whether aspirin, which has been reported as an effective drug improving
bone mineral density in human epidemiology studies, regulates the balance between bone resorption and bone formation
at stem cell levels.
Methods and Findings: We found that T cell-mediated bone marrow mesenchymal stem cell (BMMSC) impairment plays a
crucial role in ovariectomized-induced osteoporosis. Ex vivo mechanistic studies revealed that T cell-mediated BMMSC
impairment was mainly attributed to the apoptosis of BMMSCs via the Fas/Fas ligand pathway. To explore potential of using
pharmacologic stem cell based intervention as an approach for osteoporosis treatment, we selected ovariectomy (OVX)-
induced ostoeporosis mouse model to examine feasibility and mechanism of aspirin-mediated therapy for osteoporosis. We
found that aspirin can inhibit T cell activation and Fas ligand induced BMMSC apoptosis in vitro. Further, we revealed that
aspirin increases osteogenesis of BMMSCs by aiming at telomerase activity and inhibits osteoclast activity in OVX mice,
leading to ameliorating bone density.
Conclusion: Our findings have revealed a novel osteoporosis mechanism in which activated T cells induce BMMSC
apoptosis via Fas/Fas ligand pathway and suggested that pharmacologic stem cell based intervention by aspirin may be a
new alternative in osteoporosis treatment including activated osteoblasts and inhibited osteoclasts.
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Introduction
Osteoporosis is the most prevalent skeletal disorder, character-
ized by a low bone mineral density (BMD) and structural
deterioration of bone tissue, leading to bone fragility fractures
[1]. Postmenopausal osteoporosis is the most common and
significant form of osteoporosis in which estrogen deficiency gives
rise to a high turnover rate in bone metabolism, as characterized
by a over-activated osteoclast activity and a temporal increase in
osteoblast activity that is not able to balance osteoclast-mediated
bone resorption [1]. Although many systemic and local regulators
are involved in estrogen-deficient osteoporosis, it appears that
activated T lymphocyte associated osteoclast over-activation play a
pivotal role in postmenopausal osteoporosis [2–4]. Clinically,
bisphosphonates are widely used and appear to ameliorate the
effects of osteoporosis by inhibiting osteoclast functions. However,
recent experimental evidences suggest that bisphosphonates may
also inhibit apoptosis of both osteocytes and osteoblasts [5] and
increase the bone forming potential of osteoblasts [6], implying
that BMMSC/osteoblast lineage cells may actively participate in
the recovery of osteoporosis.
BMMSCs are multipotent postnatal stem cells that are capable
of differentiating into osteoblasts, chondrocytes, adipocytes,
cardiomyocytes, and myoblasts [7–9]. It is known that osteoblasts
form new bone matrix to balance osteoclast-mediated bone
resorption during the bone remodeling process so as to
maintaining homeostasis of the bone/marrow system [10]. The
interplay between the BMMSC/osteoblast lineage and hemato-
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regulating the immune system [11]. For instance, culture-
expanded BMMSCs are capable of treating T-cell-associated
disorders, such as acute graft-versus-host-disease (GVHD) through
inhibiting T lymphocyte proliferation and activity [11–13]. A
recent convergence of clinical and basic research has highlighted a
potential link between osteogenic cell death and osteoporosis
[14,15]. It has been suggested that inappropriate apoptosis of
osteoblasts/osteocytes accounts for, at least in part, the imbalance
in bone remodeling as occurs in osteoporosis, although the
elevated activity of osteoclasts is currently thought to be a
dominant factor [16,17].
The objective of this study was to investigate the effects of
activated T cells on BMMSCs in the OVX-induced osteoporosis
and examine whether aspirin, which has been identified as an
effective drug capable of improving bone mineral density in
human epidemiological studies [18,19], cures the OVX-induced
osteoporosis via regulating BMMSC function.
Materials and Methods
Antibodies
Rat anti-mouse CD3 IgG3, anti-mouse CD25 IgM, FITC- or
PE-conjugated rat anti-mouse CD25 IgG1, FITC-, PE- or PerCP-
conjugated rat anti-mouse CD4 IgG2a, and PE-conjugated rat
anti-mouse CD45R/B220 IgG2a were purchased from BD
Bioscience. Rabbit anti-human Runx2 IgG was from Oncogene.
Rabbit anti-human alkaline phosphatase (ALP) (LF47) and anti-
human osteocalcin (OCN) (LF32) were kindly provided by Dr.
Larry Fisher (National Institute of Dental and Craniofacial
Research, National Institutes of Health). Mouse anti-human b-
actin IgG was purchased from Sigma-Aldrich Co.
Animals
C3H and C3MRL-Fas
lpr mice were purchased from Jackson Lab.
The generation of ovariectomy (OVX) mice was performed the same
as described previously [20]. Anti-CD25 antibody (1 mg/mouse,
R&D system) was injected intraperitoneally into 3-month-old mice at
2 days prior to the OVX procedure. CD4
+CD25
2CD45RB
+hi
(1610
6) and CD4
+CD25
2CD45RB
2/low (1610
6) T cells isolated
fromspleenofC3Hmicebyflowcytometrywereinjectedintothetail
vein of immunocompromised mice (bg-nu/nu-xid, Harlan Sprague
Dawley Inc.). Aspirin (0.6 mg/ml, Sigma-Aldrich Co) dissolved in
water to feed mice for two months before OVX procedure. These
animal experiments were performed under an institutionally
approved protocol for the use of animal research (USC #10874
and NIDCR #03-277).
Mouse Bone Marrow Mesenchymal Stem cell (BMMSC)
culture
Mouse bone marrow cells (10–20610
6) harvested from long
bones were seeded into 100 mm culture dishes (Corning Costar
Co.), incubated for 3 hours at 37uC to allow attachment of
adherent cells, and then rinsed twice with PBS to remove the non-
adherent cells. Bone marrow cells (10–20610
6) from long bones of
guinea pigs were then added into each dish as feeder cells. To
prevent proliferation in culture, the feeder cells were c-irradiated
(Caesium-137) with 6,000 cGy by a Gammacell-1000 Irradiator
(Atomic Energy of Canada. Ltd.). BMMSCs formed adherent
colonies following 12–15 days culture. Primary cultures were
passed to disperse the colony-forming cells (passage 1). The cells at
passage 1 at ,70% confluence were utilized for the experiments.
Culture medium consisted of a-MEM (Invitrogen Corp.), 20%
fetal bovine serum (FBS; Equitech-Bio Inc.), 2 mM L-glutamine,
100 U/ml penicillin / 100 mg/ml streptomycin (Biofluids Inc),
and 55 mM 2-mercaptoethanol (2-ME). For the osteogenic
induction in vitro,2 m Mb-glycerophosphate (Sigma-Aldrich
Co.), 100 mM L-ascorbic acid 2-phosphate (Wako Pure Chemical
Industries Ltd.) and 10 nM dexamethasone (Sigma-Aldrich Co.)
were added into the culture for 6 weeks.
Human BMMSC culture
Human bone marrow aspirates from healthy human adult
volunteers (20–35 years of age) were purchased from AllCells LLC
and cultured as reported previously [21]. Single cell suspensions
(1–100610
3/well) of BMMSCs were cultured in 6-well plates
(Corning Costar Co.) with a ˜-MEM supplemented with 15% FBS,
100 mM L-ascorbic acid 2-phosphate, 2 mM L-glutamine, and
100 U/ml penicillin / 100 mg/ml streptomycin. After aspirin was
added at 2.5 mg/ml and 50 g/ml for 3–7 days, BMMSCs were
induced for osteogenic differentiation with additional 1.8 mM
KH2PO4 and then harvested for Western blot analysis.
Isolation and culture of lymph node (LN) and spleen cells
Lymph nodes were collected from axillary and submandibular
regions of mice. The LN cells (1.0–2.0610
6) were cultured with or
without plate-bounded 1 mg/ml anti-CD3 antibody and 1 mg/ml
soluble anti-CD28 antibody (BD Bioscience) in complete DMEM
containing 10% FBS for 3 days. The culture supernatant was
collected and enrichment 10 times to use as a conditioned media
(CM).
Co-culture mouse BMMSCs with LN cells
Mouse BMMSCs (200610
3/well) were plated in 24-well flat-
bottom plates (Corning Costar Co.), and cultured in mouse
BMMSC medium for 3 days. Mouse LN cells isolated from C3H
or immunocompromised mice (1610
6/well) were loaded directly
on mouse BMMSC culture or separated from mouse BMMSCs
using Transwell system (Corning Costar Co.). The co-culture
systems were cultured for 3–5 days in DMEM medium. Some of
the co-cultures were treated with 1 mg/ml anti-interferon c (IFNc)
antibody, 1 mg/ml anti-tumor necrosis factor a (TNFa) antibody,
1 mg/ml anti-Fas ligand (FasL) antibody (eBioscience or Biole-
gend), 10 mM brefeldin A (Sigma-Aldrich Co.), 100 nM con-
canamycin A (Sigma-Aldrich Co.). The cultures were washed to
remove LN cells and stained with solution containing 2%
paraformaldehyde and 2% toluidine blue or by using an
ApopTagH Peroxidase In Situ Apoptosis Detection kit (Chemicon
International, Millipore) to detect apoptotic cells.
Cell viability assay
Cell viability was assayed using Cell Counting Kit-8 (Dojindo)
according to the manufacturer’s protocol.
Transplantation of BMMSCs into immunocompromised
mice
Approximately 4.0610
6 of mouse BMMSCs were mixed with
40 mg of hydroxyapatite/tricalcium phosphate (HA/TCP) ce-
ramic powder (Zimmer Inc.) and then transplanted into the dorsal
surface of 10-week-old immunocompromised mice as previously
described [20,21]. These procedures were performed in accor-
dance to specifications of an approved small animal protocol
(USC#10874). The transplants harvested at 8 weeks post-
transplantation were fixed in 4% paraformaldehyde and then
decalcified with 10% EDTA (pH 8.0) for paraffin embedding.
Paraffin sections were deparaffinized, rehydrated, and stained with
hematoxylin and eosin (H&E). For quantification of new bone
Osteoporosis and BMMSCs
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previously described [20].
Bone analyses by micro-computed tomography
(microCT) and peripheral quantitative CT (pQCT)
Distal femoral metaphyses were analyzed by microCT (mCT-20;
SCANCO USA, Inc.). Scanning regions were confined to
secondary spongiosa and were ,0.30 mm in thickness. Using 2-
dimensional images, a region of interest was manually drawn near
the endocortical surface. Cancellous bone morphometric indices,
assessed using 3-dimensional image reconstructions, included bone
volume relative to tissue volume (BV/TV, %), trabecular thickness
(Tb.Th), trabecular number (Tb.N) and trabecular separation
(Tb.Sp). pQCT analysis of the distal femora was performed using
a XCT Research M (Stratec; Norland Co.) as previously described
[20]. Briefly, scans were obtained at 2.25 and 2.75 mm from the
distal condyles and cancellous BMD. Machine cancellous BMD
precision (based on manufacturer data) is 63 mg/cm
3 while the
coefficient of variation in our laboratory based on repeat scans was
2.26%.
Colony forming Unit fibroblasts (CFU-F) assay
The CFU-F assay was performed as previously described [20].
Cell aggregates containing more than 50 cells were counted as
colonies using a dissecting microscope. The CFU-F assay was
repeated in 5 independent experiments.
Cell proliferation assay
The proliferation of BMMSCs was assessed by bromodeoxyur-
idine (BrdU) incorporation of the cells by using a BrdU staining kit
(Invitrogen Co.) as previously described [20]. To quantify cell
proliferation capacity of the cells, ten representative images were
used to BrdU-positive cell number. Cell proliferation was shown as
a percentage of BrdU-positive cells over total nucleated cells.
In vitro mineralization assay
After 6 weeks culture of BMMSCs under osteogenic inductive
condition, calcium deposits were detected by staining with 1%
alizarin red (Sigma-Aldrich Co.). The mineralized area were
quantified by using NIH image Image-J, and shown as a
percentage of alizarin red-positive area over total area as
previously described [20].
Flowcytometric analysis
Cells isolated from mouse blood or spleen were incubated with
1 mg of FITC- or PE-conjugated mAbs for 45 min at 4uC. Isotype-
matched FITC- or PE-conjugated IgG were used as controls. After
being washed with PBS/0.4%BSA for 3 times, the cells were
analyzed by FACS
calibur (Becton Dickinson) for analysis. CD4-
positive cells were also sorted before flowcytometric analysis.
Telomerase activity
Telomerase activity in BMMSCs was detected by using a
quantitative telomerase detection (QTD) kit (Allied Biotech, Inc.)
according to the manufactures’ protocol for real-time polymerase
chain reaction (PCR) detection. Briefly, cell extraction was
prepared from human BMMSCs (100610
3), mixed with
26QTD pre-mix containing telomere primers (TTAGGG) and
iQ SYBR green supermix (BioRad Laboratories), and amplified
with an iCycler iQ real-time PCR machine (BioRad Laboratories).
The generated PCR products are directly detected by measuring
the increase in fluorescence caused by binding of SYBR Green to
double-strand DNA and calculated by using an iCycler iQ
software (BioRad Laboratories). Some cell extract was heated at
85uC for 10 min and used for negative control. The real-time
PCR condition was as follows; telomerase reaction for 20 min at
25uC, PCR initial activation step for 3 min at 95uC, 3-step cycling;
denaturation for 10 sec at 95uC, annealing for 30 sec at 60uC,
extension for 3 min at 72uC, and cycle number 40 cycles.
Measurement of telomere length
Telomere length of human BMMSCs was measured using
TeloTAGGG Telomerer Length Assay kit (Rosch, Inc.) according
to the manufacturer’s protocol. Briefly, genomic DNA was isolated
from aspirin (0, 2.5, 50 mg/mL) treated human BMMSCs, enzyme
digested and separated on 0.8% agarose gel. Blotting membrane
was hybridized with DIG probe followed by anti- DIG-AP and
substrate buffer solution, and exposed to X-ray film (Eastman
Kodak Co.). NIH image software was used for image analysis. The
mean of telomere length was calculated according to manufac-
turer’s instructions
Western blot analysis
Cells were lysed in M-PER extraction reagent (Pierce Chemical
Co.) and protein concentrations were measured using Bio-Rad
Protein Assay (Bio-Rad Laboratories Inc.). Ten micrograms of
protein were applied to each lane and separated on Tris-Glycine
SDS-PAGE gel (Novex; Invitrogen Co.). The proteins were then
transferred onto BA-S 85 nitrocellulose membranes (Schleicher &
Schuell BioScience Inc,) and blocked for 3 hours at room
temperature in NAP blocker (Geno Technology, Inc.). Antibodies
used for Western blot included: rabbit anti-alkaline phosphatase
(ALP, LF-47), osteocalcin (OCN, LF-32), runt-related transcrip-
tion factor 2 (Runx 2), b-catenin (Cell Signaling Technology Inc.,
MA), phospho-b-catenin (Cell signaling Technology inc.), and
mouse anti-b-actin antibody. Membranes were incubated with the
first antibodies (1:100–1000 dilution) for 1 hour at room
temperature and then incubated with HRP-conjugated secondary
antibodies (Santa Cruz Biotechnology, Inc.) at 1:5000 dilution for
1 hour at room temperature. Following immunolabeling, mem-
branes were washed and reacted with Super Signal chemilumi-
nescence HRP substrate (Pierce Chemical Co.) and then visualized
on Kodak X-Omat film (Eastman Kodak Co.).
Measurement of receptor activator of NFkB ligand
(RANKL), osteoprotegerin (OPG) and C-terminal
telopeptides of type I collagen
The blood was collected from retro-orbital venous plexus.
Enzyme-linked immunoassay (ELISA) was performed to detect
RANKL, OPG and C-terminal telopeptides of type I collagen in
the blood serum by using commercial kits for mTRANS/
RANKL/TNFSF11 Quantikine ELISA, mouse Osteoprote-
gerin/TNFRSF11B Quantikine ELISA Kits (R&D Systems) and
for RatLapsH ELISA kit (Nordic Bioscience Diagnostics A/S),
respectively, according to their manufactures’ instructions.
Bone analyses by histology
Femurs and Tibiae were fixed with 4% paraformaldehyde,
decalcified with 10% EDTA (pH 8.0) and embedded in paraffin.
Sections were deparaffinized and stained with hematoxylin and
eosin (H&E). Tartrate-resistant acid phosphate (TRAP) staining
was performed according to the previous report [22]. For
quantification of TRAP-positive cells in the bones, five represen-
tative images were analyzed by using an NIH Image-J. The results
were shown as the number of TRAP-positive cells per total bone
area.
Osteoporosis and BMMSCs
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Pre-osteoblasts were isolated from calvariae of 3-day-old mice
by sequential digestion with 3 mg/ml collagenase type I
(Worthington Biochemical Co.) and 4 mg/ml dispase (Boehringer
Mannheim). Bone marrow cells (200610
3/well) or spleen cells
(500610
3/well) were co-cultured with pre-osteoblasts (10610
3/
well) under the stimulation of 10 nM 1a, 25(OH)2 vitamin D3
(BIOMOL Research Laboratories, Inc.) in the 24-well culture
plates (Corning Costar Co.) for 7 days. One day after spleen cells
(1610
6/well) were seeded, 10 ng/ml macrophage colony stimu-
lating factor (R&D Systems) and 10 ng/ml RANKL (Peprotech)
were added to the culture for 5–6 days. After TRAP staining,
TRAP-positive multinucleated cells (.3 nuclei) were counted as
osteoclast-like cells.
Statistical analysis
Student’s t-test was used to analyze significance between 2
groups. A P value of less than 0.05 was considered as a significant
difference.
Results
Activated T lymphocytes induced BMMSC apoptosis
through the Fas/FasL pathway
To determine whether activated T cells directly impinge on
BMMSC survival, we used a co-culture system includingautologous
LN T cells and BMMSCs to assess the effect of T lymphocytes on
BMMSCs. When co-cultured with ex vivo expanded BMMSCs, the
naı ¨ve LN cells were unable to induce BMMSC death in vitro.
However, when LN cells were pre-activated with an anti-CD3
specific antibody, significant amount of cell death occurred in the
co-cultured BMMSCs within 12 hours (Fig. 1A). The LN T cell-
induced cell death of BMMSCs required direct cell-cell contact, as
BMMSCs co-cultured with T cells in the transwell system failed to
manifest detectable cell death (Fig. 1A). To further confirm that
observedBMMSCdeath was attributed toT cellsinLNpopulation,
we treated BMMSCs with anti-CD3 antibody pretreated LN cells
derived from T cell deficient immunocompromised mice in the
same co-culture conditions, and found no significant induction of
BMMSC death (Fig. 1B). Next, we verified that the cell death of
BMMSCs was due to apoptosis based on terminal deoxynucleotidyl
transferase-mediated dUTP-biotin nick end labeling (TUNEL)
staining (Fig. 1C) and 49,69-diamidino-2-phenylindole (DAPI)
staining (data not shown). These data indicated that activated T
cells were required to induce BMMSC death. Conversely,
conditioned supernatants collected from anti-CD3 antibody treated
LN cell cultures did not cause significant BMMSC death (Fig. 1D),
eliminating possibility that soluble factor(s) produced by activated T
cells are contributory to cell death of BMMSCs. In support of these
observations, inclusion of anti-TNFa and anti- IFN-c neutralized
antibodies in the co-cultures failed to prevent and reverse activated
T cell-mediated apoptosis of BMMCs, suggesting that TNF-a and
IFN-c were dispensable (Fig. 1E). Significantly, blockage of Fas-
FasL death pathway with either anti-FasL antibodies or a chemical
inhibitor, brefeldin A, abrogated LN cell-induced cell death of
BMMSCs, indicating the Fas/FasL pathway was critical in the
apoptosis of BMMSCs. However, concanamycin A failed to block
the activated T cell-induced cell death of BMMSCs (Fig. 1F),
Figure 1. Lymph node (LN) cells activated by an anti-CD3 antibody induce BMMSC apoptosis in vitro. (A) Mouse BMMSCs co-cultured
with LN cells indicated that anti-CD3 antibody activated LN cells were capable of inducing BMMSC death as shown a blank well without BMMSC
staining (blue). When co-cultured BMMSCs (MSC) and LN cells were separated by a transwell culture system, anti-CD3 antibody treated LN cells failed
to induce BMMSC death. (B) It is known that immunocompromised mice have no T lymphocytes. Thus, LN cells derived from immunocompromised
failed to induce BMMSC death following anti-CD3 antibody activation in the co-culture system. (C) TUNEL staining showed that BMMSC death caused
by anti-CD3 antibody-activated LN cell is through an apoptotic pathway. (D) Condition medium (CM) derived from naı ¨ve LN cells and anti-CD3
antibody activated LN cells were not able to induce cell death of BMMSCs. (E) Neutralizing anti-TNF-a and IFN-c antibodies were not able to inhibit
BMMSC death induced by anti-CD3 antibody-activated LN cells. (F) Neutralizing Fas ligand antibodies and brefeldin A, but not concanamycin A, were
capable of blocking BMMSC death induced by anti-CD3 antibody-activated LN cells. (G) Western blot analysis showed that mouse and human
BMMSCs (mMSC and hMSC) express Fas. (H) Fas antibody can induce significant reduction in number of living BMMSCs in culture. (I) Anti-CD3
antibody-activated LN cells were not able to induce cell death of BMMSCs derived from CD95-deficient mice (lpr). (n=5; [P,0.05 and [[[P,0.005).
doi:10.1371/journal.pone.0002615.g001
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Indeed, we also found that BMMSCs expressed Fas as determined
by Western blot analysis (Fig. 1G) and agonistic anti-Fas antibody
was capable of inducing apoptosis of human BMMSCs in vitro
(Fig. 1H). Also, anti-CD3 antibody stimulated spleen cells were
capable of inducing apoptosis of BMMSCs and osteoblast-like
MG63 cells (data not shown). Finally, we verified that activated T
cells failed to induce apoptosis of BMMSCs derived from CD95-
deficient (lpr/lpr) mice (Fig. 1I).
CD4
+CD25
2CD45RB
+hi T cell infusion resulted in BMMSC
impairment in OVX immunocompromised mice
To examine whether T cell can impair BMMSC in vivo,w e
adoptively transferred CD4
+CD25
2CD45RB
+hi T cells, previously
showed to induce inflammatory bowel disease (IBD) in nude mice
[23] and in patients with IBD associated osteoporosis [24,25],
into OVX immunocompromised mice that lacked osteoporosis
phenotype due to the absence of T lymphocytes (Fig. 2A).
OVX-immunocompromised mouse is an established model
with inducible osteoporosis phenotype that allows testing whether
CD4
+CD25
2CD45RB
+hi T cell can induce osteoporosis like bone
density alteration in vivo.W ei s o l a t e dC D 4
+CD25
2CD45RB
+hi and
CD4
+CD25
2CD45RB
2/low T cells from the spleens of C3H mice
(Fig. 2B) and intravenously infused into immunocompromised mice.
One month after the infusion, the typical trabecular bone resorption
and lumbar BMD reduction were observed in OVX-immunocom-
promised mice that received CD4
+CD25
2CD45RB
+hi T cells, but
not CD4
+CD25
2CD45RB
2/low Tc e l l s( F i g .2 C ) ,s u g g e s t i n gt h a t
CD4
+CD25
2CD45RB
+hi T cells were responsible, at least in great
part, for T-cell-associated osteoporosis. Next, we assessed whether
Figure 2. Adoptive transfer of CD4
+CD25
2CD45RB
+hi T cells derived from C3H mice restores bone loss phenotype in OVX-
immunocompromised mice. (A) Estrogen-deficiency failed to induce osteoporosis in 15-week-old bg-nu/nu-xid immunocompromised mice. At
one-month post-OVX, there is no BMD difference in femurs between OVX and sham group (n=4), assessed by Dual x-ray absorptiometry (DEXA)
analysis. The graph represents mean6SD. (B) Isolation of CD4
+CD25
2CD45RB
+hi (open arrow) and CD4
+CD25
2CD45RB
2/low (triangle arrow) T cells
from spleen of C3H mice by flow cytometry for systemic infusion. (C) At one month post-OVX, DEXA analysis revealed a significant decreased BMD in
the femurs of CD4
+CD25
2CD45RB
+hi OVX mice (OVX+T
RB+hi) when compared to the OVX mice (OVX) or CD4
+CD25
2CD45RB
2/low OVX mice
(OVX+T
RB2/low;n=4 ;[ [ P,0.01). (D) The number of CFU-F decreased significantly in CD4
+CD25
2CD45RB
+hi OVX mice (OVX+T
RB+hi) compared to OVX
and CD4
+CD25
2CD45RB
2/low OVX mice (OVX+T
RB2/low). Totally 10
6 all nuclear cells (ANC) were used in each group. Error bars represent the
mean6SD (n=5; [[P,0.01). (E) The proliferation of BMMSCs from CD4
+CD25
2CD45RB
+hi OVX mice (OVX+T
RB+hi) was significantly increased in
compared to CD4
+CD25
2CD45RB
2/low OVX mice (OVX+T
RB2/low) and OVX mice as assessed by BrdU incorporation assay for 24 hours. The number of
BrdU-positive cells was indicated as a percentage to the total number of counted BMMSCs and averaged from 5 replicated cultures. Error bars
represent the mean6SD (n=5; [[P,0.001). (F) Alizarin red staining showed that BMMSCs derived from CD4
+CD25
2CD45RB
+hi OVX mice (OVX+T
RB+hi)
had lower calcium accumulation than that of BMMSCs from OVX and CD4
+CD25
2CD45RB
2/low OVX mice (OVX+T
RB2/low) when cultured under the
osteogenic inductive conditions. The graph represents mean6SD (OVX mice, n=4; CD4
+CD45RB
+hi OVX mice, n=5; CD4
+CD45RB
2/low OVX mice,
n=4; [P,0.001). (G) BMMSCs were transplanted into immunocompromised mice using HA/TCP (HA) as a carrier for eight weeks. Bone formation
assessed by H&E staining was decreased in transplants of BMMSCs derived from CD4
+CD25
2CD45RB
+hi OVX mice (OVX+T
RB+hi) compared to BMMSC
transplants of OVX and CD4
+CD25
2CD45RB
2/low OVX mice (OVX+T
RB2/low). B; bone CT; connective tissue. Original magnification; 6200. The graph
represents mean6SD (OVX mice, n=4; CD4
+CD45RB
+hi OVX mice, n=5; CD4
+CD45RB
2/low OVX mice, n=4; [P,0.001). (H) TRAP staining showed that
15-week old OVX mice received CD4
+CD45RB
hi cells (OVX+T
RB+hi) contain elevated number of TRAP-positive osteoclastic cells (white arrows) in
epiphysis and trabecular bone areas of femurs as compared to Sham, OVX, and OVX received CD4
+CD45RB
2/low cells (OVX+T
RB2/low). The graph
represents mean6SD (n=4; [P,0.05, [[P,0.01). BM: bone marrow, TB: trabecular bone.
doi:10.1371/journal.pone.0002615.g002
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immunocompromised mice receiving CD4
+CD25
2CD45RB
+hi T
cells. By examining the CFU-F efficiency, an assay representing the
number of clonogenic mesenchymal progenitors, we found a
significantly decreased number of CFU-F in
CD4
+CD25
2CD45RB
+hi cell-treated OVX-immunocompromised
mice compared to the un-treated or CD4
+CD25
2CD45RB
2/low T
cell-treated OVX-immunocompromised animals (Fig. 2D). In
addition, the proliferation of BMMSCs from
CD4
+CD25
2CD45RB
+hi T cell-treated OVX-immunocompro-
mised mice was also dramatically increased compared to the other
two groups, as assessed by the BrdU incorporation assay (Fig. 2E).
Moreover, we found that the systemic infusion of
CD4
+CD25
2CD45RB
+hi T cells led to an impaired osteogenic
differentiation of BMMSCs, as shown by decreased mineralization
accumulation in osteogenic inductive cultures (Fig. 2F) and reduced
bone formation when transplanted subcutaneously into immuno-
compromised mice (Fig. 2G). It is known that elevated osteoclast
activity plays a major role in osteoporosis. Here we found that the
number of TRAP-positive osteoclasts was significantly increased in
CD4
+CD25
2CD45RB
+hi T cell-treated OVX-immunocompro-
mised mice compared to the control groups (Fig. 2H). Taken
together, the data indicated that both impaired BMMSCs and
activated osteoclast activity in CD4
+CD25
2CD45RB
+hi Tc e l l -
treated OVX-immunocompromised mice contributed to the osteo-
porosis phenotype.
Aspirin recovered OVX-induced osteoporosis by
improving osteogenesis and inhibiting
osteoclastogenesis
It was known that aspirin improves bone density in aged
population [18,19], therefore, we examined whether aspirin affects
Fas-induced BMMSC apoptosis and found that indeed aspirin is
capable of inhibiting Fas antibody-induced cell death of BMMSCs
(Fig. 3A) and specifically inducing death of activated T cells
(Fig. 3B and 3C). To elucidate the role of aspirin in osteoporosis
treatment, we used OVX mice treated with low dose aspirin for
three months (Fig 3D). Using microQCT analysis we found that
aspirin treatment significantly improved trabecular and cortical
bone density in OVX mice (Figs. 3E–3G). In addition, aspirin
treatment suppressed OVX-induced high number of CFU-F and
proliferation rate of BMMSCs (Figs. 3H and 3I). When BMMSCs
were transplanted into immunocompromised, the aspirin treated
mice showed elevated bone-forming capacity (Fig. 3J). To further
examine the mechanism of aspirin-mediated improvement of
osteogenesis, we revealed that aspirin treatment was capable of
promoting mineral accumulation of human BMMSCs in osteo-
inductive cultures (Fig. 3K) and significantly increased bone
formation when these BMMSCs were subcutaneously transplanted
into immunocompromised mice (Fig. 3L). Previously, it was
reported that telomerase activation in BMMSCs improves
osteogenesis and adipogenesis [21]. Thus, we examined whether
aspirin treatment elevated telomerase activity in BMMSCs as seen
in epithelial cells [26]. As expected, we found that aspirin
treatment slightly raised telomerase activity in BMMSCs
(Fig. 3M) and their telomere lengths (Fig. 3N). The underlying
mechanisms of aspirin effect on bone metabolism appear to
correlate with increased expression of certain osteogenic genes
including Runx2, a master gene for osteogenic differentiation,
ALP, and OCN (Fig. 3O). Additionally, ex vivo aspirin treatment
was capable of accelerating degradation of phospho-b-catenin
(Fig. 3P), resulting in an increased level of WNT signaling, a
recognized pathway in osteogenesis. Since a balance between bone
formation and resorption is required for maintaining bone
integrity in the remodeling process. We further examine the role
of aspirin on osteoclast activity and found that long–term aspirin
treatment can systemically alter several serum markers, reduced
RANKL and increased OPG in OVX mice (Fig. 4A). Although we
found a decreased level of C-terminal telopeptide in aspirin treated
OVX mice, it failed to show a statistically significant difference
(Fig. 4A). Histological sections showed a marked decrease in
TRAP-positive cells in the tibia of aspirin treated OVX mice in
comparison to the OVX and sham mice (Fig. 4B). Further studies
using osteoclast progenitors derived from the bone marrow and
spleen co-cultured with pre-osteoblasts from calvariae revealed
that TRAP-positive multinucleated cells (TRAP
+-MNCs) signifi-
cantly decreased in the aspirin-treated group in a dose-dependent
manner (Fig. 4C). Additionally, ex vivo aspirin treatment can block
RANKL-induced osteoclastogenesis (Fig. 4D). Taken together,
these data indicated that aspirin is capable of improving bone
formation and inhibiting bone resorption through multiple
mechanisms.
Discussion
Aspirin may contribute to multiple biological pathways, such as
inhibiting COX2 and COX1, and PG2 activities. This makes it
difficult to elucidate the detailed functional mechanism of aspirin
in relation to bone remodeling. Epidemiological studies reported
that the regular use of aspirin or nonsteroidal anti-inflammatory
drugs (NSAIDs) may have a moderate beneficial effect on BMD in
postmenopausal woman [18], however, there appears no clinically
significant protective effect on the subsequent risk of fractures [19].
This discrepancy may be linked to the multiple functional roles of
aspirin where its activity may largely depend on the in vivo
microenvironment. Moreover, diversified functional roles of
aspirin make it unlikely that any single pathway contributes solely
to its anti-apoptotic effect on BMMSCs. In this study, we found
that aspirin was able to up-regulate telomerase activity as seen in
other cell types [26] with capability to increase bone formation
[21]. We speculate that up-regulated telomerase activity in
BMMSCs resulted in aspirin-mediated osteogenesis, suggesting
that aspirin could serve a potential treatment of osteoporosis in the
OVX mice. Aspirin-elevated telomerase level in BMMSCs is
much lower than that in cancer cells, implying a safe use of aspirin
to improve osteogenesis.
Although it has been proposed that anti-osteogenic cell
apoptosis or improved osteogenic cell function is an effective
approach for osteoporosis treatment [27] as occurs with the
application of PTH [28], simultaneously targeting of osteoclasts
and osteoblasts to treat osteoporosis may be a more potent
therapeutic approach. Despite the fact that well-developed anti-
osteoclast drugs, such as bisphosphonates and strontium, have
achieved reasonable therapeutic effects in osteoporosis patients
[29,30], their functions may also involve an independent effect on
improving osteogenic cell function [6,31]. More importantly, it is
necessary to examine whether this combination therapy is a
superior choice for the treatment of osteoporosis than the currently
available therapeutic regimen.
It has been reported that the adoptive transfer of T cells can
restore OVX-induced bone loss in nude mice [32]. Transfer of
CD4
+CD45RB
+hi T cells to immune-deficient recipients leads to
the development of IBD [23,33]. In contrast, transfer of the
reciprocal CD4
+CD45RB
2/low population not only failed to
induce colitis, but also prevented it [34]. Interestingly, patients
with IBD often have decreased bone mass, an increased risk of
developing osteoporosis, and associated fragility fractures and
morbidity [35,36]. Although osteoclasts and osteoblasts are
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PLoS ONE | www.plosone.org 6 July 2008 | Volume 3 | Issue 7 | e2615Figure 3. Aspirin treatment induces activated T cell death in vitro, promotes osteogenesis of BMMSCs, and improves BMD in OVX
mice. (A) Fas Ab can induce significantly reduction in number of living BMMSCs in the culture. However, the cell viability of human BMMSCs was
significantly improved in aspirin (ASP)-treated groups (n=5, [[[P,0.005 vs. untreated control group; ###P,0.005 vs. Fas Ab-treated group). (B)
Aspirin (ASP) did not affect the cell viability of whole LN cells cultured on regular plate. (C) On the other hand, T cells activated by cultured on
CD3eAb-coated dishes showed decreased viability in 50 mg/ml ASP-treated group, but not in 2.5 mg/ml ASP-treated group. (n=5, [P,0.05 vs. 0 mg/
ml ASP group; #P,0.05 vs. 2.5 mg/ml ASP group). (D) The scheme indicates the experimental design on aspirin administration and OVX surgery
procedure. (E) Trabecular bone structure of the distal femoral metaphysis was analyzed by microQCT. As expected OVX mice showed decreased
trabecular bone (yellow circle area) and cortical bone (arrow) formation when compared to sham mice. Aspirin treated OVX mice exhibited a
significant increase in trabecular bone (yellow circle area) and cortical bone (arrow) volume compared to OVX mice. (F,G) MicroQCT analysis
demonstrated that BV/TV (bone volume vs. tissue volume) (F) and Tb.N (trabecular number) (G) were decreased in OVX mice as compared to sham
group but significantly increased in aspirin treated OVX group (n=5; [P,0.01). (H) The number of CFU-F in OVX group increased significantly as
compared to sham group, however, aspirin treatment (OVX+A) appeared to reduce CFU-F number to the sham group level. Error bars represent the
mean6SD (n=5, [[P,0.01). (I) The proliferation rate of BMMSCs was assessed by BrdU incorporation assay for 24 hours. The number of BrdU-positive
cells was indicated as a percentage to the total number of counted BMMSCs and averaged from 5 replicated cultures. BMMSCs derived from OVX
mice showed significantly elevated BrdU-uptake rate, however, aspirin treatment (OVX+A) reduced BrdU up-take rate. Error bars represent the
mean6SD (n=5, [P,0.01, [[P,0.001). (J) BMMSCs from aspirin treated mice were transplanted into immunocompromised mice for eight weeks using
HA/TCP (HA) as a carrier vehicle. Bone formation assessed by H&E staining was decreased in OVX BMMSC transplants compared to sham mouse
group. Aspirin treatment (OVX+A) can improve OVX BMMSC-mediated bone formation in vivo. B; bone CT; connective tissue. Original magnification;
6200. The bone formation rate was calculated as the percentage of newly formed bone area per total area of transplant at the representative cross-
sections. The graph represents mean6SD (sham mice, n=4; OVX mice, n=4; OVX+A mice, n=4; [P,0.01). (K) Representative images of Alizarin red
staining of human BMMSCs cultured under the osteogenic inductive condition containing 2.5 and 50 mg/ml aspirin (ASP 2.5 mg/ml and ASP 50 mg/
ml). Aspirin treatment can increase calcium accumulation in cultured human BMMSCs. (L) After aspirin treatment at 50 mg/ml for 1 week, ex vivo
expanded human BMMSCs were transplanted into immunocompromised mice with HA/TCP (HA) as a carrier. Aspirin treated human BMMSCs
exhibited significantly increased new bone formation in comparison to non-aspirin-treated control human BMMSC transplants ([ P,0.05). (M) Human
BMMSCs express low levels of telomerase activity (MSC), if there is any. Following 1-week aspirin treatment (2.5 or 50 mg/ml), human BMMSCs
showed a significantly increased telomerase activity (MSC+A) ([ P,0.01). HEK293 cells were used as a positive control (239T) and heat inactive human
BMMSCs were used as negative control (H.I). (N) Aspirin treatment at 2.5 mg/ml (Asp 2.5) and 50 mg/ml (Asp 50) can slightly increased telomere
length from 6.4 kb in un-treated control group (Asp 0) to 7.7 kb (Asp 2.5) and 7.6 (Asp 50) respectively. 293T cell line (12.1 kb) was used as a positive
control. (O) Western blot analysis showed that aspirin treatment (ASP) at indicated dosages enables to elevate expressions of Runx2, alkaline
phosphatase (ALP), and osteocalcin (OCN). b-actin was used a control for the amount of sample loading. (P) Human BMMSCs were cultured with or
without aspirin at 50 mg/ml for 0, 0.5, 1, 2, 3 hours. The degradation of phospho-b-catenin was accelerated in aspirin (50 mg/ml) treated group. b-
actin was used a control for the amount of sample loading.
doi:10.1371/journal.pone.0002615.g003
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precise mechanisms of action remain unclear, especially whether
activated T cells act on osteogenic progenitor cells is currently
unknown. Therefore, in this study we applied a widely used T-cell
adoptive transfer system in mice to elucidate the association
between CD4
+CD45RB
+hi T cells and BMMSCs, adding a
potential mechanism that may contribute to the bone phenotype
in osteoporosis patients. More importantly, we provided direct
evidences to support the notion that interplays between T cells and
BMMSCs through Fas/FasL signaling pathway may be critical for
pathogenesis of osteoporosis.
The Fas/FasL system is a physiologically important pathway for
the regulation of tumor cell proliferation and suppression of
immune response. Deregulation of Fas/FasL leads to various
severe clinical disorders associated with uncontrolled T cell
proliferation, such as organ transplantation graft rejection,
systemic lupus erythematosus, Sjogren’s syndrome, and lymphoid
tumors [37]. FasL was originally discovered on cells of the
lymphoid/myeloid lineage, including activated T cells, where it
plays an important role in immune homeostasis and T cell- and
NK cell-mediated toxicity [38]. Expression of FasL in activated T
lymphocytes plays an important role in Fas-mediated tumor
killing. It has been reported that osteoblasts express Fas and the
FasL/Fas pathway involved in osteogenic cell apoptosis in
response to glucocorticoids [39]. Here, we found that BMMSCs
are akin to osteoblasts expressing Fas. In our study, activated T
lymphocytes can trigger BMMSC apoptosis, predominantly
through the FasL/Fas pathway, supporting the notion that Fas
antigen is involved in BMMSC death in vivo [40]. In contrast, the
perforin-based pathway, another major mechanism of cell-
mediated cytotoxicity, is not involved in activated T cell-mediated
BMMSC apoptosis. In this study, we used LN cells to interact with
BMMSCs, where the LN population contains both inflammatory
and regulatory T cell populations. Other cell types such as
macrophages and dendritic cells (DCs) may participate in T cell
activation in our co-culture system. Further studies are needed to
determine whether and how each subset of T cell affects BMMSC
apoptosis.
In summary, this study revealed that activated T lymphocytes
are responsible for the BMMSC apoptosis through the Fas/FasL
pathway, resulting in accelerating osteoporosis phenotype in OVX
mice. Moreover, we found that pharmacologic regulation of
BMMSCs by aspirin may offer a new approach for estrogen-
deficient osteoporosis treatment.
Figure 4. Aspirin treatment inhibits osteoclast activities. (A) OVX mice have increased levels of RANKL and type I collagen C-terminal
telopeptides and decreased levels of OPG in blood serum as compared to sham mice. Aspirin treated OVX mice (OVX+A) showed a significant
decreased levels of RANKL and type I collagen C-terminal telopeptides along with increased levels OPG in blood serum. The graph represents
mean6SD (n=5; [P,0.01 vs. Sham; #P,0.05 vs. OVX). (B) TRAP staining confirmed that OVX mice had increased number of TRAP positive cells in
epiphysis and trabecular bone areas of the distal femurs as compared to sham mice. Administration of aspirin for three months resulted in a
significant decrease in number of TRAP positive cells (OVX+A) in the epiphysis and trabecular bone areas (n=6; [[[P,0.005 vs. Sham; ###P,0.005
vs. OVX). (C) Ex vivo co-culture bone marrow cells or spleen cells with osteoblastic cells revealed that in vitro aspirin treatment inhibits the formation
of TRAP-positive multinuclear cells (MNCs) in a dose dependent manner (2–200 mg/ml). The graph represents mean6SD (n=5; [[[P,0.005 vs. ASP
0 mg/mL). (D) RANKL-induced osteoclastogenesis was partially blocked by aspirin treatment at 50 mg/ml as seen a significantly decreased number of
TRAP-positive osteoclasts in aspirin treated group (ASP 50). The graph represents mean6SD (n=5; [[[P,0.005 vs. ASP 0 mg/mL).
doi:10.1371/journal.pone.0002615.g004
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